SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, demonstrating IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme, 3CLpro, making it an attractive candidate for intervention strategies. SARS-CoV-2-IN-11 holds significant promise in the development of specific antivirals against SARS-CoV-2.

SARS-CoV-2 3CLpro-IN-11(11d) is a broad-spectrum antiviral compound that effectively inhibits the SARS-CoV-2 3CL protease, achieving an IC50 of 140 nM. Additionally, it exhibits inhibitory activity against SARS-CoV-1 and MERS-CoV with IC50 values of 240 nM and 70 nM, respectively.

SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue that contains higher stability in human plasma and liver S9 enzymes assay than niclosamide. It improves bioavailability and half-life when administered orally. SARS-CoV-2-IN-15 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.49 μM [1].

Covidcil-19 binds to the revised attenuator hairpin structure of the SARS-CoV-2 frameshifting element (FSE) with high affinity (Kd = 11 nM). It stabilizes the hairpin's folded state and reduces frameshifting efficiency in cells. Covidcil-19 inhibits viral propagation and reduces viral infectivity by > 3.5 orders of magnitude.

Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 treatment. However, its authorization was withdrawn in April 2021 due to emerging SARS-CoV-2 variants resistant to the antibody [1].

Mpro inhibitor N3 hemihydrate is a potent antagonist of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 of 16.77 μM against SARS-CoV-2. It exhibits specific inhibition of Mpro in a range of coronaviruses, including SARS-CoV and MERS-CoV. Furthermore, it effectively inhibits HCoV-229E, FIPV, and MHV-A59, with IC50 values of 4.0 μM, 8.8 μM, and 2.7 μM, respectively[1][2].